Eling Pharmaceutical announced that the company recently received the “Notice of Acceptance” approved and issued by the State Drug Administration. The application for clinical trials of the innovative chemical drug LB220-D08 extended-release tablets was accepted. The acceptance numbers are CXHL2600983 and CXHL2600984. The acceptance date is August 12, 2026. This drug is a new class 1 chemical drug independently developed by the company. It is a complement inhibitor targeting factor B and is indicated for atypical hemolytic-uremic syndrome.

Eling Pharmaceutical announced that the company recently received the “Notice of Acceptance” approved and issued by the State Drug Administration. The application for clinical trials of the innovative chemical drug LB220-D08 extended-release tablets was accepted. The acceptance numbers are CXHL2600983 and CXHL2600984. The acceptance date is August 12, 2026. This drug is a new class 1 chemical drug independently developed by the company. It is a complement inhibitor targeting factor B and is indicated for atypical hemolytic-uremic syndrome.